Digene — Merger or Acquisition (June 2007)
35 slides from Digene's merger presentation, Jun 4, 2007
Slide 1: QIAGEN and DIGENE Announce Merger
Exhibit 99.1 June 4, 2007, 8:30am EST, 13:30 GMT, 14:30 CET QIAGEN and DIGENE Announce Merger A New Market and Technology Leader in Molecular Diagnostics Conference Call Outline: 1. 30 min Presentation Peer M. Schatz, CEO, QIAGEN Roland Sackers, CFO, QIAGEN Daryl J. Faulkner, CEO, DIGENE Joe P. Slat
Slide 2: Joint Safe Harbor
Joint Safe Harbor Remarks that we make during this call about future expectations, plans and prospects may include forward-looking statements. There are risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements,
Slide 3: Transaction Overview
Transaction Overview Purchase Price: US$ 61.25 per share, a 37% premium to prior close Purchase Consideration: DIGENE shareholders may elect to receive for each DIGENE share either US$ 61.25 per share in cash or 3.545 QIAGEN shares, subject to pro ration (55%/45% cash/stock) Pro forma Ownership: QIA
Slide 4: QIAGEN and DIGENE at a Glance
QIAGEN / DIGENE Investor Call, June 4, 2007 Sample & Assay Technologies Revenues Operating income US$ millions 550 500 450 400 350 300 250 200 150 100 50 0 Operating income 2003 2004 2005 2006 2007E 160 140 120 100 Revenues CAGR 2003-2006 32% US$ millions DIGENE figures converted to calendar year (C
Slide 5: Overview of DIGENE Corporation
Listing: NASDAQ: DIGE -4-
Slide 6: QIAGEN and DIGENE: A Decade-Long Partnership in Molecular Diagnostics
Overview of DIGENE Corporation Leader in key segment of MDx: HPV testing The DIGENE® HPV Test portfolio is the only FDA-approved test portfolio for the human papillomavirus (HPV) Exclusive IP positions on key high-risk types Regulatory leadership Focus on women’s health Portfolio includes molecular
Slide 7: The Combination Accelerates DIGENE's Commercialization and Development Goals
QIAGEN and DIGENE A Decade-Long Partnership in Molecular Diagnostics 10+ year partnership between QIAGEN and DIGENE DIGENE products integrate QIAGEN sample and assay technologies Example: Rapid Capture® system Core platform of DIGENE FDA-listed instrument Co-developed and manufactured by QIAGEN DIGE
Slide 8: The Combination Accelerates QIAGEN's Molecular Strategy
The Combination Accelerates DIGENE’s Commercialization and Development Goals Highly attractive consideration for DIGENE shareholders Significant premium and value delivered today Significant combined upside potential QIAGEN’s unparalleled sample and assay technology breadth creates opportunities for
Slide 9: The Combination Creates Real Value
The Combination Accelerates QIAGEN’s Molecular Strategy DIGENE’s highly focused strategy in MDx is a exceptional fit with QIAGEN QIAGEN’s strategy: leadership in “Sample & Assay Technologies” – in research, pharma, applied testing and MDx Same target customers in MDx Superb brands and reputations HP
Slide 10: Highly Synergistic Capabilities and Assets
The Combination Creates Real Value VALUE Market and technology leadership in molecular diagnostics* Over $350 million of molecular diagnostics revenue Targeting > $800 million in total revenues in 2008 Unique technology and product portfolio Leading in breadth and depth in molecular testing Leader i
Slide 11: Highly Synergistic Capabilities and Assets QIAGEN DIGENE Run-rate Sales as of Q1 '07
Highly Synergistic Capabilities and Assets QIAGEN DIGENE Run-rate Sales as of Q1 '07 512 210 Sales in MDx 154 210 (approximately) Sales strength Global North America Sales force in MDx 150 170 (approximately) Clinical Laboratories, Sales force target in MDx Clinical Laboratories Physicians Broad: 12
Slide 12: Combined Revenue Distribution – Highly Complementary
- 10 -
Slide 13: Combined Revenue Distribution (continued)
Combined Revenue Distribution – Highly Complementary Based on Q1 2007 All figures are estimates + By Product Groups Consumables Consumables Consumables 89% 92% 90% Instruments Instruments Instruments 8% 10% 10% By Customer Groups AT AT MDx 11% MDx 8% 27% Research MDx 48% 20% Research 100% Pharma 27%
Slide 14: A Critical Disease Target: Human Papilloma Virus (HPV)
36% 46% 39% America 52% 85% QIAGEN / DIGENE Investor Call, June 4, 2007 Sample & Assay Technologies - 11 -
Slide 15: DIGENE HPV Test is Playing a Key Role in Women's Health
A Critical Disease Target: Humanpapilloma Virus (HPV) Cervical cancer is the #2 cancer for women worldwide WW over 470K cases/year causing more than 230K deaths In the US almost 10K cases/year, almost 4K deaths One woman dies every two minutes from cervical cancer HPV is the proven cause of cervical
Slide 16: Significant Untapped Potential for HPV Testing
DIGENE HPV Test is Playing a Key Role in Women’s Health Cervical cancer is more prevalent in women age >30 1/3 of cervical cancers in woman with a normal Pap Clinical practice guidelines now recommend combined screening (HPV+Pap for women >30 yrs) The DIGENE HPV Test Clinical results published on >
Slide 17: Vaccines are a Compelling Growth Driver for HPV Testing
Significant Untapped Potential for HPV Testing U.S. Current tests: Penetration rate: ~8.4M Europe ~22% Current tests: Penetration rate: ~2.0M Asia/Latin America: ~6% Current tests: Penetration rate: 0.9M ~3% Increasing adoption into medical guidelines Vaccine campaigns to promote awareness of HPV an
Slide 18: Tangible Opportunities for Future Growth Synergies
Vaccines are a Compelling Growth Driver for HPV Testing Significant marketing budgets advocating importance Target age groups Target vaccination age: 11-12 years Approved vaccination age: 9 to 26 years Target testing age: >30 years It would take >20 years to phase in Vaccinations Limited to 2 “high
Slide 19: QIAGEN and DIGENE - Direct Neighbors
Tangible Opportunities for Future Growth Synergies Exciting near-term product synergies: Multiplexing technologies for future genotyping application Sample preparation Next-generation assay technologies Assay breadth in woman’s health Exciting other synergies include: QIAGEN is key supplier to vacci
Slide 20: World-Class Capabilities and Organization to Ensure Success
QIAGEN and DIGENE - Direct Neighbors Germantown and Gaithersburg MD Companies are 5 minutes apart (2.8 miles) QIAGEN / DIGENE Investor Call, June 4, 2007 Sample & Assay Technologies - 17 -
Slide 21: A New Leader in Molecular Diagnostics
World-Class Capabilities and Organization to Ensure Success Great management breadth and depth Strong leaders from both companies Leading expertise in molecular diagnostics and life sciences Strong foundation for collaboration built upon 10+ year partnership Similar cultures and strong working relat
Slide 22: Financial Rationale
A New Leader in Molecular Diagnostics Consistent with strategies of both companies QIAGEN: leadership in sample and assay technologies – in research, pharma, applied testing and MDx DIGENE: a leader in HPV; poised for next wave of growth Creating a new leader in MDx with broad synergies Technology C
Slide 23: QIAGEN + DIGENE Revenue Growth 2003 – 2007E
Financial Rationale Enhancing revenue and EPS growth Revenue synergy opportunities Cost synergy opportunities Accretive to adjusted EPS in the first year after closing Significantly accretive to 2009 EPS and EPS growth thereafter Strong cash flow generation Revenue Enhancing - Accretive – Cash Flow
Slide 24: QIAGEN + DIGENE Operating Income 2003 – 2007E
QIAGEN + DIGENE Revenue Growth 2003 – 2007E US$ millions CAGR Q 2003-2006 = 15% CAGR D 2003-2006 = 32% CAGR Total 2003-2006 = 19% DIGENE QIAGEN QIAGEN revenues excluding the synthetic DNA business unit, sold in Q2 2004 DIGENE revenues converted to calendar year (CY) QIAGEN – Continuous Double Digit
Slide 25: QIAGEN + DIGENE Net Income 2003 – 2007E
QIAGEN + DIGENE Operating Income 2003 – 2007E1 US$ millions CAGR Q 2003-2006 = 17% CAGR D 2003-2006 = 235% CAGR Total 2003-2006 = 25% DIGENE QIAGEN 1. Operating income excludes acquisition, integration and relocation related charges, as well as amortization of acquired IP and equity-based compensati
Slide 26: Synergy Opportunities – Near and Long Term
QIAGEN + DIGENE Net Income 2003 – 2007E1 US$ millions DIGENE QIAGEN CAGR Q 2003-2006 = 22% CAGR D 2003-2006 = 157% CAGR Total 2003-2006 = 31% 1. Net income excludes acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R
Slide 27: Contribution to Fiscal Year 2007
Synergy Opportunities – Near and Long Term Cost synergies – Near and long term Savings of US$35 million to US$45 million in 2008 Sustainable reduction of cost of goods sold Eliminated redundant expenses, public company costs Augmented R&D capabilities to drive product development Expanded applicabil
Slide 28: Contribution and Accretion to Fiscal Year 2008
Contribution to Fiscal Year 2007 Q3 2007 Assumes current consensus estimates for DIGENE Revenue and EPS allocation dependent on final closing date Expected adj. EPS1 for the third quarter approx. US$ (0.01) – (0.02) Q4 2007 Net sales, US$ m2 58 - 60 Adj. EPS, US$1 (0.03) – (0.04) 1. Adjusted EPS exc
Slide 29: Combined Financial Strength
Contribution and Accretion to Fiscal Year 2008 All figures reflect calendar year estimates Net sales, US$ m FY 2008 Synergy revenues 260 - 270 Instrument and other product sales to DIGENE + Net sales, US$ m - Adj. Operating margin1 260 - 270 Adj. EPS, US$1 28% - 30% 0.02 – 0.04 1. Adjusted operating
Slide 30: Roadmap to Completion
Combined Financial Strength Strong balance sheet Equity ratio: > 45 % Strong cash flow generation Cash flow in 2008: > US$100 million EBITDA 2008: > US$250 million Mid term outlook / strong margin improvement Organic Revenue growth: > 15% Adj. EPS1 growth: > 20% Gross Margin: > 70% Operating Margin:
Slide 31: Transaction Highlights
Roadmap to Completion Commence exchange offer for both cash and stock in June Queen shareholder vote in early July HSR approval Complete Tender Offer Transaction close expected August/September 2007 QIAGEN / DIGENE Investor Call, June 4, 2007 - 28 - Sample & Assay Technologies
Slide 32: Questions and Answers
Transaction Highlights Creation of a market and technology leader in MDx* QIAGEN’s breadth in sample and assay technologies meets DIGENE’s leadership in a key segment of MDx Unique technology, content and product portfolio Comprehensive sales and marketing channel to realize technology potential Exc
Slide 33: Disclaimer Regarding Forward-Looking Statements
Questions and Answers QIAGEN / DIGENE Investor Call - June 4, 2007 Sample & Assay Technologies - 30 -
Slide 34: Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking …
Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward- looking statements include, but are not limited to, statements about the anticipated benefits of QIAGEN’s
Slide 35: the exchange offer. These documents contain important information about the transaction and should be
the exchange offer. These documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders will be able to obtain free copies of these documents through the website maintained by the Securities